152 related articles for article (PubMed ID: 33402494)
1. CD133 Expression Predicts Relapse in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemotherapy.
Oi H; Okuyama T; Miyazaki S; Ono Y; Oya M
In Vivo; 2021; 35(1):437-445. PubMed ID: 33402494
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
Okuyama T; Sameshima S; Takeshita E; Yoshioka R; Yamagata Y; Ono Y; Tagaya N; Noie T; Oya M
World J Surg Oncol; 2018 Jun; 16(1):105. PubMed ID: 29871650
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
4. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Sclafani F; Brown G; Cunningham D; Rao S; Tekkis P; Tait D; Morano F; Baratelli C; Kalaitzaki E; Rasheed S; Watkins D; Starling N; Wotherspoon A; Chau I
Oncologist; 2017 Jun; 22(6):728-736. PubMed ID: 28476941
[TBL] [Abstract][Full Text] [Related]
5. Indications for neoadjuvant treatment based on risk factors for poor prognosis before and after neoadjuvant chemotherapy alone in patients with locally advanced rectal cancer.
Ogura A; Uehara K; Aiba T; Sando M; Tanaka A; Ohara N; Murata Y; Sato Y; Hattori N; Nakayama G; Ebata T; Kodera Y; Nagino M
Eur J Surg Oncol; 2021 May; 47(5):1005-1011. PubMed ID: 33189492
[TBL] [Abstract][Full Text] [Related]
6. [Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy].
Cai C; Wang J; Zhong Z; Dai Z; Wang Q; Dong W; Shi H; Liu Q; DU J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):36-43. PubMed ID: 28436629
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
8. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
9. [Expression of CD133 in rectal cancer tissues and its relationship with neoadjuvant chemoradiotherapy].
Li D; Wu H; Feng R; Zhong D; Luo Y; Xiao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):690-4. PubMed ID: 27353106
[TBL] [Abstract][Full Text] [Related]
10. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
Seddik Y; Brahmi SA; Afqir S
Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
[TBL] [Abstract][Full Text] [Related]
11. Impact of RAS/BRAF mutation status in locally advanced rectal cancer treated with preoperative chemotherapy.
Oshiro T; Uehara K; Aiba T; Mukai T; Ebata T; Nagino M
Int J Clin Oncol; 2018 Aug; 23(4):681-688. PubMed ID: 29478127
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial.
Tomida A; Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Okada Y; Kurumiya Y; Nakayama G; Nakamura M; Aiba T; Nagino M;
Int J Clin Oncol; 2019 Apr; 24(4):403-410. PubMed ID: 30471067
[TBL] [Abstract][Full Text] [Related]
13. Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
Chang H; Tao YL; Jiang W; Chen C; Liu SL; Ye WJ; Gao YH
BMC Cancer; 2020 Jun; 20(1):498. PubMed ID: 32487091
[TBL] [Abstract][Full Text] [Related]
14. Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer.
Zhang Y; Yan L; Wu Y; Xu M; Liu X; Guan G
BMC Cancer; 2020 Sep; 20(1):854. PubMed ID: 32891131
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
Kondo K; Matsusaka S; Ishihara S; Horie H; Uehara K; Oguchi M; Murafushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Fujii M; Nakajima T
Radiother Oncol; 2019 May; 134():199-203. PubMed ID: 31005216
[TBL] [Abstract][Full Text] [Related]
16. Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
Sun Y; Wu X; Zhang Y; Lin H; Lu X; Huang Y; Chi P
Eur J Surg Oncol; 2019 Jul; 45(7):1225-1231. PubMed ID: 30879932
[TBL] [Abstract][Full Text] [Related]
17. Impact of Fluoropyrimidine and Oxaliplatin-based Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.
Okada Y; Ozawa T; Hayama T; Ohno K; Tsukamoto M; Fukushima Y; Shimada R; Nozawa K; Matsuda K; Hashiguchi Y
In Vivo; 2021; 35(1):593-601. PubMed ID: 33402514
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
19. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.
Sclafani F; Brown G; Cunningham D; Wotherspoon A; Tait D; Peckitt C; Evans J; Yu S; Sena Teixeira Mendes L; Tabernero J; Glimelius B; Cervantes A; Thomas J; Begum R; Oates J; Chau I
Ann Oncol; 2016 Aug; 27(8):1557-65. PubMed ID: 27217542
[TBL] [Abstract][Full Text] [Related]
20. Is neoadjuvant chemoradiotherapy always necessary for mid/high local advanced rectal cancer: A comparative analysis after propensity score matching.
Zhang Y; Sun Y; Xu Z; Chi P; Lu X
Eur J Surg Oncol; 2017 Aug; 43(8):1440-1446. PubMed ID: 28502421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
